Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 2, 2026 · Leadership change · Other material event
ONCOLYTICS BIOTECH INC
7
Leadership change
Jun 2, 2026
| Item 5.02 | Director or executive officer departure or appointment |
| Item 8.01 | Other events the company considers material |
ONCOLYTICS BIOTECH INC filed this to disclose a change in directors or executive officers: appointments, departures, or role changes that can signal a strategic shift.
Oncolytics Biotech ® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer SAN DIEGO, CA, June 2, 2026 – Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and t…
This filing reports Item 5.02 (director or executive officer departure or appointment); Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
ONCOLYTICS BIOTECH INC reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
